Samani NJ van der Harst P Biological ageing and cardiovascular disease Heart 2008 94 537-539 
Fuster JJ Andr&#233;s V Telomere biology and cardiovascular disease Circ Res 2006 99 1167-1180 
Aviv A Telomeres and human somatic fitness J Gerontol A Biol Sci Med Sci 2006 61 871-873 
Kimura M Hjelmborg JB Gardner JP Short leukocyte telomeres forecast mortality: a study in elderly Danish twins Am J Epidemiol 2008 167 799-806 
Bakaysa SL Mucci LA Slagboom PE Telomere length predicts survival independent of genetic influences Aging Cell 2007 6 769-774 
Njajou OT Cawthon RM Damcott CM Telomere length is paternally inherited and is associated with parental lifespan Proc Natl Acad Sci U S A 2007 104 12135-12139 
Bekaert S De Meyer T Rietzschel ER Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease Aging Cell 2007 6 639-647 
Spyridopoulos I Erben Y Brummendorf TH Telomere gap between granulocytes and lymphocytes is a determinant for hematopoetic progenitor cell impairment in patients with previous myocardial infarction Arterioscler Thromb Vasc Biol 2008 28 968-974 
Brouilette SW Moore JS McMahon AD Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study Lancet 2007 369 107-114 
van der Harst P van der Steege G de Boer RA Telomere length of circulating leukocytes is decreased in patients with chronic heart failure J Am Coll Cardiol 2007 49 1459-1464 
O&#8217;Donnell CJ Demissie S Kimura M Leukocyte telomere length and carotid artery intimal medial thickness: The Framingham Heart Study Arterioscler Thromb Vasc Biol 2008 28 1165-1171 
Okuda K Bardeguez A Gardner JP Telomere length in the newborn Pediatr Res 2002 52 377-381 
Akkad A Hastings R Konje JC Telomere length in small-for-gestational-age babies BJOG 2006 113 318-323 
Martin-Ruiz CM Gussekloo J van Heemst D Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study Aging Cell 2005 4 287-290 
Ehrlenbach S Willeit P Kiechl S Influences on the reduction of relative telomere length over 10 years in the population-based Bruneck Study: introduction of a well-controlled high-throughput assay Int J Epidemiol 2009 38 6 1725-1734 
Aviv A Chen W Gardner JP Leukocyte telomere dynamics: longitudinal findings among young adults in the Bogalusa Heart Study Am J Epidemiol 2009 169 323-329 
Nordfj&#228;ll K Svenson U Norrback KF Adolfsson R Lenner P Roos G The individual blood cell telomere attrition rate is telomere length dependent PLoS Genet 2009 5 2 e1000375 
Farzaneh-Far R Lin J Epel E Telomere length trajectory and its determinants in persons with coronary artery disease: longitudinal findings from the heart and soul study PloS One 2010 5 1 e8612 
Farzaneh-Far R Lin J Epel E Harris WS Blackburn EH Whooley MA Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease JAMA 2010 303 250-257 
Aviv A The epidemiology of human telomeres: faults and promises J Gerontol A Biol Sci Med Sci 2008 63 979-983 
Berenson GS McMahan CA Voors AW Cardiovascular Risk Factors in Children&#8212;The Early Natural History of Atherosclerosis and Essential Hypertension. 1980 New York Oxford University Press 47-123 
Kimura M Stone RC Hunt SC Measurement of telomere length by the southern blot analysis of the terminal restriction fragment lengths Nature Protocols 2010 5 1596-1607 
Kuh D A life course perspective on telomere length and social inequalities in aging Aging Cell 2006 5 579-580 
Xu Q Parks CG DeRoo LA Multivitamin use and telomere length in women Am J Clin Nutr 2009 89 1857-1863 
Mov&#233;rare-Skrtic S Svensson J Karlsson MK Serum insulin-like growth factor-I concentration is associated with leukocyte telomere length in a population-based cohort of elderly men J Clin Endocrinol Metab 2009 94 5078-584 
Lansdorp PM Stress, social rank and leukocyte telomere length Aging Cell 2006 5 583-584 
Cawthon RM Telomere measurement by quantitative PCR Nucleic Acids Res 2002 30 e47 
Aviv A Valdes AM Spector TD Human telomere biology: pitfalls of moving from the laboratory to epidemiology Int J Epidemiol 2006 35 1424-1429 
Shen J Terry MB Gurvich I Short telomere length and breast cancer risk: a study in sister sets Cancer Res 2007 67 5538-5544 
Rufer N Br&#252;mmendorf TH Kolvraa S Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood J. Exp. Med 1999 190 157-167 
Zeichner SL Palumbo P Feng Y Rapid telomere shortening in children Blood 1999 93 2824-2830 
Frenck RW Jr. Blackburn EH Shannon KM The rate of telomere sequence loss in human leukocytes varies with age Proc Natl Acad Sci U S A 1998 95 5607-5610 
Sidorov I Kimura M Yashin A Leukocyte telomere dynamics and human hematopoietic stem cell kinetics during somatic growth Exp Hematol 2009 37 514-524 
Barbieri M Paolisso G Kimura M Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects Mech Ageing Dev 2009 130 771-776 
Hunt SC Chen W Gardner JP Leukocyte telomeres are longer in African Americans than in whites: the National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study Aging Cell 2008 7 451-458 
Jeanclos E Schork NJ Kyvik KO Telomere length inversely correlates with pulse pressure and is highly familial Hypertension 2000 36 195-200 
Vasan RS Demissie S Kimura M Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study Circulation 2008 117 1138-1144 
Nawrot TS Staessen JA Gardner JP Telomere length and possible link to X chromosome Lancet 2004 363 507-510 
Fitzpatrick AL Kronmal RA Gardner JP Leukocyte telomere length and cardiovascular disease in the Cardiovascular Health Study Am J Epidem 2007 165 14-21 
Benetos A Okuda K Lajemi M Telomere length as indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity Hypertension 2001 37 part 2 381-385 
Valdes A Andrew T Gardner JP Obesity, cigarette smoking, and telomere length in women Lancet 2005 66 662-664 
Kim S Parks CG DeRoo LA Obesity and weight gain in adulthood and telomere length Cancer Epidemiol Biomarkers Prev 2009 18 816-820 
Nordfj&#228;ll K Eliasson M Stegmayr B Lundin S Roos G Nilsson PM Increased abdominal obesity, adverse psychosocial factors and shorter telomere length in subjects reporting early ageing; the MONICA Northern Sweden Study Scand J Public Health 2008 36 744-752 
Gardner JP Li S Srinivasan SR Rise in insulin resistance is associated with escalated telomere attrition Circulation 2005 111 2171-2177 
Scher AI Midgette LA Lipton RB Risk factors for headache chronification Headache 2008 48 1 16-25 
Niv D Devor M Chronic pain as a disease in its own right Pain Pract 2004 4 3 179-181 
Sicuteri F Quasi-phantom head pain from functional deafferentation Clin J Pain 1987 3 63-80 
Prakash S Shah ND Delayed response of indomethacin in patients with hemicrania continua: real or phantom headache? Cephalalgia 2010 30 3 375-379 
Marmura MJ Pello SJ Young WB Interictal pain in cluster headache Cephalalgia 2010 30 12 1531-1534 
Harris AJ Cortical origin of pathological pain Lancet 1999 354 9188 1464-1466 
Flor H Nikolajsen L Staehelin Jensen T Phantom limb pain: a case of maladaptive CNS plasticity? Nat Rev Neurosci 2006 7 11 873-881 
Lake AE III Chronic daily headache in the absence of medication overuse: is daily or continuous pain more treatment-resistant than chronic daily headache with pain-free days? Curr Pain Headache Rep 2005 9 1 4-6 
Vanast WJ New daily persistent headaches definition of a benign syndrome Headache 1986 26 317 
Li D Rozen TD The clinical characteristics of new daily persistent headache Cephalalgia 2002 22 1 66-69 
Takase Y Nakano M Tatsumi C Matsuyama T Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan Cephalalgia 2004 24 11 955-959 
Prakash S Shah ND Post-infectious new daily persistent headache may respond to intravenous methylprednisolone J Headache Pain 2010 11 1 59-66 
Evans RW New daily persistent headache Curr Pain Headache Rep 2003 7 4 303-307 
Choi DS Choi DY Whittington RA Nedeljkovi&#263; SS Sudden amnesia resulting in pain relief: the relationship between memory and pain Pain 2007 132 1&#8211;2 206-210 
Farrell MJ Katz B Helme RD The impact of dementia on the pain experience Pain 1996 67 1 7-15 
Scherder E Herr K Pickering G Gibson S Benedetti F Lautenbacher S Pain in dementia Pain 2009 145 3 276-278 
Pickering G Jourdan D Dubray C Acute versus chronic pain treatment in Alzheimer&#8217;s disease Eur J Pain 2006 10 4 379-384 
Kunz M Scharmann S Hemmeter U Schepelmann K Lautenbacher S The facial expression of pain in patients with dementia Pain 2007 133 1&#8211;3 221-228 
Cole LJ Farrell MJ Duff EP Barber JB Egan GF Gibson SJ Pain sensitivity and fMRI pain-related brain activity in Alzheimer&#8217;s disease Brain 2006 129 Pt 11 2957-2965 
Ringman JM Romano JD Medina LD Rodriguez-Agudelo Y Schaffer B Varpetian A Increased prevalence of significant recurrent headache in preclinical familial Alzheimer&#8217;s disease mutation carriers Dement Geriatr Cogn Disord 2008 25 4 380-384 
Takeshima T Taniguchi R Kitagawa T Takahashi K Headaches in dementia Headache 1990 30 11 735-738 
Nampiaparampil DE Prevalence of chronic pain after traumatic brain injury: a systematic review JAMA 2008 300 6 711-719 
Couch JR Bearss C Chronic daily headache in the post trauma syndrome: relation to extent of head injury Headache 2001 41 6 559-564 
Formisano R Buzzi MG Bivona U Matteis M Caltagirone C Assessing cognitive and psychological patterns in posttraumatic headache following severe brain injury J Neurotrauma 2002 19 1366 
Solomon S Post-traumatic headache: commentary: an overview Headache 2009 49 7 1112-1115 
May A Chronic pain may change the structure of the brain Pain 2008 137 7-15 
Apkarian AV Bushnell MC Treede RD Zubieta JK Human brain mechanisms of pain perception and regulation in health and disease Eur J Pain 2005 9 4 463-484 
Svoboda E McKinnon MC Levine B The functional neuroanatomy of autobiographical memory: a meta-analysis Neuropsychologia 2006 44 12 2189-2208 
Diesch E Flor H Alteration in the response properties of primary somatosensory cortex related to differential aversive Pavlovian conditioning Pain 2007 131 1&#8211;2 171-180 
Morgane PJ Galler JR Mokler DJ A review of systems and networks of the limbic forebrain/limbic midbrain Prog Neurobiol 2005 75 2 143-160 
Guidetti V Galli F Psychiatric comorbidity in chronic daily headache: pathophysiology, etiology, and diagnosis Curr Pain Headache Rep 2002 6 6 492-497 
Fenton BW Limbic associated pelvic pain: a hypothesis to explain the diagnostic relationships and features of patients with chronic pelvic pain Med Hypotheses 2007 69 2 282-286 
Turk CD Wilson HD Fear of pain as a prognostic factor in chronic pain: conceptual models, assessment, and treatment implications Curr Pain Headache Rep 2010 14 88-95 
Lackner JM Lou Coad M Mertz HR Wack DS Katz LA Krasner SS Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety Behav Res Ther 2006 44 5 621-638 
Shaw WS Means-Christensen AJ Slater MA Webster JS Patterson TL Grant I Psychiatric disorders and risk of transition to chronicity in men with first onset low back pain Pain Med 2010 11 1391-1400 
Apkarian AV Pain perception in relation to emotional learning Curr Opin Neurobiol 2008 18 4 464-468 
Giummarra MJ Gibson SJ Georgiou-Karistianis N Bradshaw JL Central mechanisms in phantom limb perception: the past, present and future Brain Res Rev 2007 54 219-232 
Wiech K Ploner M Tracey I Neurocognitive aspects of pain perception Trends Cogn Sci 2008 12 8 306-313 
Lai CH Hsu YY A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6&#160;weeks&#8217; duloxetine therapy Int J Neuropsychopharmacol 2010 22 1-11 
Barrios V Escobar C Calder&#243;n A Llisterri JL Alegr&#237;a E Mu&#241;iz J Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis J Cardiometab Syndr 2007 2 9-15 
Schillaci G Pirro M Vaudo G Gemelli F Marchesi S Porcellati C Prognostic value of the metabolic syndrome in essential hypertension J Am Coll Cardiol 2004 43 1817-1822 
Liu SJ Guo ZR Hu XS Wu M Chen FM Kang GD Risks for type-2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome the study from Jiangsu, China of 5 years follow-up Diabetes Res Clin Pract 2008 81 117-123 
Elliott WJ Meyer PM Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis Lancet 2007 369 201-207 
Bakris GL Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker J Clin Hypertens 2008 10 27-32 
Mancia G Laurent S Agabiti-Rosei E Ambrosioni E Burnier M Caulfield MJ Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document Blood Press 2009 18 308-347 
Bakris G Molitch M Hewkin A Kipnes M Sarafidis P Fakouhi K Bacher P Sowers J STAR investigators. differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome Diabetes Care 2006 29 2592-2597 
Kintscher U Bramlage P Paar WD Thoenes M Unger T Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two-armed study in 14&#8201;200 patients Cardiovasc Diabetol 2007 6 12 
Heidemann C Sun Q van Dam RM Meigs JB Zhang C Tworoger SS Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women Ann Intern Med 2008 149 307-316 
Sj&#246;holm A Nystr&#246;m T Inflammation and the etiology of type 2 diabetes Diabetes Metab Res Rev 2006 22 4-10 
Rubin D Claas S Pfeuffer M Nothnagel M Foelsch UR Schrezenmeir J s-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal Lipids Health Dis 2008 7 32 
Fabia MJ Abdilla N Oltra R Fernandez C Redon J Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24&#8201;h ambulatory blood pressure monitoring J Hypertens 2007 25 1327-1336 
Mason RP Marche P Hintze TH Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine Arterioscler Thromb Vasc Biol 2003 23 2155-2163 
Fogari R Preti P Zoppi A Mugellini A Corradi L Lazzari P Santoro T Derosa G Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients Intern Med 2008 47 1851-1857 
Alberti KG Zimmet P Shaw J The metabolic syndrome-a new worldwide definition Lancet 2005 366 1059-1062 
Hansson L Hedner T Dahl&#246;f B Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials Blood Press 1992 1 113-119 
Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia WHO: Geneva, Switzerland 2006 
Wallace TM Levy JC Matthews DR Use and abuse of HOMA modeling Diabetes Care 2004 27 1487-1495 
Law MR Wald NJ Morris JK Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials BMJ 2003 326 1427-1431 
Wald DS Law M Morris JK Bestwick JP Wald NJ Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11&#8201;000 participants from 42 trials Am J Med 2009 122 290-300 
Chrysant SG Melino M Karki S Lee J Heyrman R The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study Clin Ther 2008 30 587-604 
Punzi HA Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide Expert Rev Cardiovasc Ther 2009 7 229-239 
De Pablos-Velasco PL Mart&#237;nez-Mart&#237;n FJ Rodr&#237;guez-P&#233;rez F Prevalence of obesity in a Canarian community. Association with type 2 diabetes mellitus: the Gu&#237;a Study Eur J Clin Nutr 2002 56 557-560 
Borch-Johnsen K Wareham N The rise and fall of the metabolic syndrome Diabetologia 2010 53 597-599 
Ninomiya T Kiyohara Y Albuminuria and chronic kidney disease in association with the metabolic syndrome J Cardiometab Syndr 2007 2 104-107 
Gerstein HC Mann JF Yi Q Zinman B Dinneen SF Hoogwerf B Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals JAMA 2001 286 421-426 
Ibsen H Olsen MH Wachtell K Borch-Johnsen K Lindholm LH Mogensen CE Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study Hypertension 2005 45 198-202 
Bakris G Stockert J Molitch M Zhou Q Champion A Bacher P Risk factor assessment for new onset diabetes: literature review Diabetes Obes Metab 2009 11 177-187 
Chobanian AV Bakris GL Black HR Cushman WC Green LA Izzo JL Jr The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report JAMA 2003 289 2560-2572 
Kaplan NM The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide Hypertension 2009 54 951-953 
Eriksson JW Jansson PA Carlberg B H&#228;gg A Kurland L Svensson MK Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) study Hypertension 2008 52 1030-1037 
Cooper-DeHoff RM Wen S Beitelshees AL Zineh I Gums JG Turner ST Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications Hypertension 2010 55 61-68 
Alderman MH New-onset diabetes during antihypertensive therapy Am J Hypertens 2008 21 493-499 
Alderman MH Is new-onset diabetes mellitus important? Yes, but&#8230; High Blood Pres &amp; Cardiovasc Prev 2008 15 5-8 
Bakris G Molitch M Zhou Q Sarafidis P Champion A Bacher P Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study J Cardiometab Syndr 2008 3 18-25 
Aguilar D Solomon SD K&#248;ber L Rouleau JL Skali H McMurray JJ Newly diagnosed and previously known diabetes mellitus and 1&#8211;year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial Circulation 2004 110 1572-1578 
Jamerson K Weber MA Bakris GL Dahl&#246;f B Pitt B Shi V Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 2008 359 2417-2428 
Matsui Y Eguchi K O&#8242;Rourke MF Ishikawa J Miyashita H Shimada K Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients Hypertension 2009 54 716-723 
Fliser D Buchholz K Haller H Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertension patients with microinflammation Circulation 2004 110 1103-1107 
Smith DH Neutel JM Lacourci&#232;re Y Kempthorne-Rawson J Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements J Hypertens 2003 21 1291-1298 
Clegg J Murphy E Almack K Harvey A Tensions around inclusion: reframing the moral horizon Journal Applied Research in Intellectual Disabilities 2008 21 81-94 
Cummins RA Lau ALD Community integration or community exposure? A review and discussion in relation to people with ID Journal Applied Research in Intellectual Disabilities 2003 16 145-57 
Department of Health &amp; Social Security Report of the Committee of Inquiry into Allegations of Ill-Treatement of Patients and Other Irregularities at the Ely Hospital, Cardiff 1969 London HMSO 
Douglas M Risk and Blame: Essays in Cultural Theory 1992 London Routledge 
Felce D Can person-centred planning fulfil a strategic planning role? Journal Applied Research in Intellectual Disabilities 2004 17 27-30 
Forrester-Jones R Carpenter J Coolen-Schrijner P Cambridge P Tate A Beecham J The social networks of people with ID living in the community 12 years after resettlement from long-stay hospitals Journal Applied Research in Intellectual Disabilities 2006 19 285-95 
Gleeson B Kearns R Remoralising landscapes of care Environment and Planning D: Society and Space 2001 19 61-80 
Hallam A Beecham J Knapp M Carpenter J Cambridge P Forrester-Jones R Service use and costs of support 12 years after leaving hospital Journal Applied Research in Intellectual Disabilities 2006 19 296-308 
Healthcare Commission Investigation into the service for people with learning disabilities provided by Sutton and Merton Primary Care Trust 2007a Available at:
Healthcare Commission Action plan by Sutton and Merton PCT in response to the Healthcare Commission's investigation into services for people with learning disabilities at the trust &#8211;&#8216;final version&#8217; 15 March 2007 2007b Available at:
Healthcare Commission Healthcare commission corporate plan 2007&#8211;8 2007c Available at:
O'Brien J Wilcox B , Bellamy GT A guide to lifestyle planning A Comprehensive Guide to the Activities Catalog 1987 Baltimore, MD Paul H. Brookes 175-189 
Poncelas A Murphy G Accessible information for people with intellectual disabilities: do symbols really help? Journal Applied Research in Intellectual Disabilities 2007 20 466-74 
Power M The Audit Society: Rituals of Verification 1997 Oxford Oxford University Press 
Public Expenditure Statistical Analysis Trends in public expenditure 2008 Available at:
Stronach I Vaughan M Inspection and justice: HMI and Summerhill school Summerhill &amp; A.S.Neill 2006 Maidenhead Open University Press 118-136 
Thomson M The Problem of Mental Deficiency: Eugenics, Democracy and Social Policy in Britain c1870&#8211;1959 1998 Oxford Clarendon Press 
Trent JW Inventing the Feeble Mind: A History of Mental Retardation in the US 1994 Los Angeles, CA University of California Press 
Wolfensberger W Glenn L Program Analysis of Service Systems (PASS) 1972 Toronto National Institute on Mental Retardation 
Porter PL Global trends in breast cancer incidence and mortality Salud P&#250;blica M&#233;x 2009 51 Suppl 2 s141-s146 
Travis RC Reeves GK Green J Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study Lancet 2010 375 9732 2143-2151 
Buck MB Knabbe C TGF-&#946; signaling in breast cancer Ann NY Acad Sci 2006 1089 119-126 
Dijke P Hill CS New insights into TGF-&#946;-Smad signalling Trends Biochem Sci 2004 29 5 265-273 
Moustakas A Heldin CH Non-Smad TGF-&#946; signals J Cell Sci 2005 118 Pt 16 3573-3584 
Zhang YE Non-Smad pathways in TGF-&#946; signaling Cell Res 2009 19 1 128-139 
Lee MK Pardoux C Hall MC TGF-&#946; activates Erk MAP kinase signalling through direct phosphorylation of ShcA EMBO J 2007 26 17 3957-3967 
Bhowmick NA Zent R Ghiassi M Integrin &#946; 1 signaling is necessary for transforming growth factor-&#946; activation of p38MAPK and epithelial plasticity J Biol Chem 2001 276 50 46707-46713 
Edlund S Landstrom M Heldin CH Transforming growth factor-&#946;-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA Mol Biol Cell 2002 13 3 902-914 
Wilkes MC Murphy SJ Garamszegi N Cell-type-specific activation of PAK2 by transforming growth factor &#946; independent of Smad2 and Smad3 Mol Cell Biol 2003 23 23 8878-8889 
Barcellos-Hoff MH Akhurst RJ Transforming growth factor-&#946; in breast cancer: too much, too late Breast Cancer Res 2009 11 1 202 
Kleuser B Malek D Gust R 17-&#946;-estradiol inhibits transforming growth factor-&#946; signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30 Mol Pharmacol 2008 74 6 1533-1543 
Hinshelwood RA Huschtscha LI Melki J Concordant epigenetic silencing of transforming growth factor-&#946; signaling pathway genes occurs early in breast carcinogenesis Cancer Res 2007 67 24 11517-11527 
Akhurst RJ Derynck R TGF-&#946; signaling in cancer&#8211;a double-edged sword Trends Cell Biol 2001 11 11 S44-S51 
Turashvili G Bouchal J Baumforth K Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis BMC Cancer 2007 7 55 
Figueroa JD Flanders KC Garcia-Closas M Expression of TGF-&#946; signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics Breast Cancer Res Treat 2010 121 3 727-735 
Xu J Lamouille S Derynck R TGF-&#946;-induced epithelial to mesenchymal transition Cell Res 2009 19 2 156-172 
Miyazono K Transforming growth factor-&#946; signaling in epithelial-mesenchymal transition and progression of cancer Proc Jpn Acad B Phys Biol Sci 2009 85 8 314-323 
Massagu&#233; J TGF&#946; in cancer Cell 2008 134 2 215-230 
Dijke P Goumans MJ Pardali E Endoglin in angiogenesis and vascular diseases Angiogenesis 2008 11 1 79-89 
Flavell RA Sanjabi S Wrzesinski SH The polarization of immune cells in the tumour environment by TGF-&#946;. Nature reviews Immunology 2010 10 8 554-567 
Buijs JT Henriquez NV Overveld PG Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer Cancer Res 2007 67 18 8742-8751 
Bos PD Nguyen DX Massagu&#233; J Modeling metastasis in the mouse Curr Opin Pharmacol 2010 10 5 571-577 
Tsuji T Ibaragi S Hu GF Epithelial-mesenchymal transition and cell cooperativity in metastasis Cancer Res 2009 69 18 7135-7139 
Grunert S Jechlinger M Beug H Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nature reviews Molec Cell Biol 2003 4 8 657-665 
Padua D Zhang XH Wang Q TGF-&#946; primes breast tumors for lung metastasis seeding through angiopoietin-like 4 Cell 2008 133 1 66-77 
Godde NJ Galea RC Elsum IA Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions J Mammary Gland Biol Neoplasia 2010 15 2 149-168 
Zavadil J Bottinger EP TGF-&#946; and epithelial-to-mesenchymal transitions Oncogene 2005 24 37 5764-5774 
Miettinen PJ Ebner R Lopez AR TGF-&#946; induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors J Cell Biol 1994 127 6 Pt 2 2021-2036 
Piek E Moustakas A Kurisaki A TGF-(&#946;) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells J Cell Sci 1999 112 Pt 24 4557-4568 
Lindley LE Briegel KJ Molecular characterization of TGF&#946;-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells Biochem Biophys Res Commun 2010 399 4 659-664 
Jo M Lester RD Montel V Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling J Biol Chem 2009 284 34 22825-22833 
Trimboli AJ Fukino K Bruin A Direct evidence for epithelial-mesenchymal transitions in breast cancer Cancer Res 2008 68 3 937-945 
Turashvili G Bouchal J Ehrmann J Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 2007 151 1 59-64 
Micalizzi DS Farabaugh SM Ford HL Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression J Mammary Gland Biol Neoplasia 2010 15 2 117-134 
Christofori G New signals from the invasive front Nature 2006 441 7092 444-450 
Vincent T Neve EP Johnson JR A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-&#946; mediated epithelial-mesenchymal transition Nat Cell Biol 2009 11 8 943-950 
Thuault S Valcourt U Petersen M Transforming growth factor-&#946; employs HMGA2 to elicit epithelial-mesenchymal transition J Cell Biol 2006 174 2 175-183 
Viloria-Petit AM David L Jia JY A role for the TGF&#946;-Par6 polarity pathway in breast cancer progression Proc Natl Acad Sci USA 2009 106 33 14028-14033 
Shirakihara T Horiguchi K Miyazawa K TGF-&#946; regulates isoform switching of FGF receptors and epithelial-mesenchymal transition EMBO J 2011 30 4 783-795 
Wendt MK Smith JA Schiemann WP Transforming growth factor-&#946;-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression Oncogene 2010 29 49 6485-6498 
Micalizzi DS Christensen KL Jedlicka P The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-&#946; signaling J Clin Invest 2009 119 9 2678-2690 
Micalizzi DS Wang CA Farabaugh SM Homeoprotein Six1 increases TGF-&#946; Type I receptor and converts TGF-&#946; signaling from suppressive to supportive for tumor growth Cancer Res 2010 70 24 10371-10380 
Deckers M Dinther M Buijs J The tumor suppressor Smad4 is required for transforming growth factor &#946;-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells Cancer Res 2006 66 4 2202-2209 
Thuault S Tan EJ Peinado H HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition J Biol Chem 2008 283 48 33437-33446 
Gregory PA Bert AG Paterson EL The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 Nat Cell Biol 2008 10 5 593-601 
Bakin AV Tomlinson AK Bhowmick NA Phosphatidylinositol 3-kinase function is required for transforming growth factor &#946;-mediated epithelial to mesenchymal transition and cell migration J Biol Chem 2000 275 47 36803-36810 
Graauw M Miltenburg MH Schmidt MK Annexin A1 regulates TGF-&#946; signaling and promotes metastasis formation of basal-like breast cancer cells Proc Natl Acad Sci USA 2010 107 14 6340-6345 
Araki S Eitel JA Batuello CN TGF-&#946;1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer J Clin Investig 2010 120 1 290-302 
Mareel M Oliveira MJ Madani I Cancer invasion and metastasis: interacting ecosystems Virchows Archiv: An International Journal of Pathology 2009 454 6 599-622 
Mareel M Leroy A Clinical, cellular, and molecular aspects of cancer invasion Physiol Rev 2003 83 2 337-376 
Hu M Yao J Carroll DK Regulation of in situ to invasive breast carcinoma transition Cancer Cell 2008 13 5 394-406 
Luo YP Zhou H Krueger J The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression Oncogene 2010 29 5 662-673 
Mandal S Johnson KR Wheelock MJ TGF-&#946; induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways Exp Cell Res 2008 314 19 3478-3493 
Giampieri S Manning C Hooper S Localized and reversible TGF-&#946; signalling switches breast cancer cells from cohesive to single cell motility Nat Cell Biol 2009 11 11 1287-1296 
McAllister SS Weinberg RA Tumor-host interactions: a far-reaching relationship J Clin Oncol: Official Journal of the American Society of Clinical Oncology 2010 28 26 4022-4028 
Park CC Bissell MJ Barcellos-Hoff MH The influence of the microenvironment on the malignant phenotype Mol Med Today 2000 6 8 324-329 
Mueller MM Fusenig NE Friends or foes - bipolar effects of the tumour stroma in cancer Nat Rev Cancer 2004 4 11 839-849 
Sieweke MH Bissell MJ The tumor-promoting effect of wounding: a possible role for TGF-&#946;-induced stromal alterations Crit Rev Oncog 1994 5 2&#8211;3 297-311 
Shekhar MP Pauley R Heppner G Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast Breast Cancer Res 2003 5 3 130-135 
Olsen CJ Moreira J Lukanidin EM Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts BMC Cancer 2010 10 444 
Stuelten CH Busch JI Tang B Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-&#946; mediated mechanism in a mouse xenograft model of breast cancer PLoS ONE 2010 5 3 e9832 
Karnoub AE Dash AB Vo AP Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature 2007 449 7162 557-563 
Haviv I Polyak K Qiu W Origin of carcinoma associated fibroblasts Cell Cycle 2009 8 4 589-595 
Kojima Y Acar A Eaton EN Autocrine TGF-&#946; and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts Proc Natl Acad Sci USA 2010 107 46 20009-20014 
Bhowmick NA Chytil A Plieth D TGF-&#946; signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia Science 2004 303 5659 848-851 
Cheng N Bhowmick NA Chytil A Loss of TGF-&#946; type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-&#945;-, MSP- and HGF-mediated signaling networks Oncogene 2005 24 32 5053-5068 
Cheng N Chytil A Shyr Y Transforming growth factor-&#946; signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion Molec Cancer Res 2008 6 10 1521-1533 
Barcellos-Hoff MH Ravani SA Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells Cancer Res 2000 60 5 1254-1260 
Barcellos-Hoff MH Radiation-induced transforming growth factor &#946; and subsequent extracellular matrix reorganization in murine mammary gland Cancer Res 1993 53 17 3880-3886 
Casey TM Eneman J Crocker A Cancer associated fibroblasts stimulated by transforming growth factor &#946;1 (TGF-&#946;1) increase invasion rate of tumor cells: a population study Breast Cancer Res Treat 2008 110 1 39-49 
Mantovani A Marchesi F Porta C Inflammation and cancer: breast cancer as a prototype Breast 2007 16 Suppl 2 S27-S33 
Bierie B Moses HL TGF-&#946; and cancer Cytokine Growth Factor Rev 2006 17 1&#8211;2 29-40 
Marigo I Dolcetti L Serafini P Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells Immunol Rev 2008 222 162-179 
Gallina G Dolcetti L Serafini P Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells J Clin Investig 2006 116 10 2777-2790 
Yang L Huang J Ren X Abrogation of TGF-&#946; signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis Cancer Cell 2008 13 1 23-35 
Oliveira MJ Damme J Lauwaet T &#946;-casein-derived peptides, produced by bacteria, stimulate cancer cell invasion and motility EMBO J 2003 22 22 6161-6173 
Leask A Abraham DJ TGF-&#946; signaling and the fibrotic response FASEB J: Official Publication of the Federation of American Societies for Experimental Biology 2004 18 7 816-827 
Kang Y He W Tulley S Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway Proc Natl Acad Sci USA 2005 102 39 13909-13914 
Alarmo EL Parssinen J Ketolainen JM BMP7 influences proliferation, migration, and invasion of breast cancer cells Cancer Lett 2009 275 1 35-43 
Ketolainen JM Alarmo EL Tuominen VJ Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4 Breast Cancer Res Treat 2010 124 2 377-386 
Alarmo EL Korhonen T Kuukasjarvi T Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas Ann Oncol: Official Journal of the European Society for Medical Oncology/ESMO 2008 19 2 308-314 
Blair HC Athanasou NA Recent advances in osteoclast biology and pathological bone resorption Histol Histopathol 2004 19 1 189-199 
Henderson MA Danks JA Slavin JL Parathyroid hormone-related protein localization in breast cancers predict improved prognosis Cancer Res 2006 66 4 2250-2256 
Powell GJ Southby J Danks JA Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites Cancer Res 1991 51 11 3059-3061 
Guise TA Yin JJ Taylor SD Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis J Clin Investig 1996 98 7 1544-1549 
Yin JJ Selander K Chirgwin JM TGF-&#946; signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development J Clin Invest 1999 103 2 197-206 
Kakonen SM Selander KS Chirgwin JM Transforming growth factor-&#946; stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways J Biol Chem 2002 277 27 24571-24578 
Evtimova V Schwirzke M Tarbe N Identification of breast cancer metastasis-associated genes by chip technology Anticancer Res 2001 21 6A 3799-3806 
Watson MA Ylagan LR Trinkaus KM Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients Clin Cancer Res: An Official Journal of the American Association for Cancer Research 2007 13 17 5001-5009 
Lu X Wang Q Hu G ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis Genes Dev 2009 23 16 1882-1894 
Kang Y Massagu&#233; J Epithelial-mesenchymal transitions: twist in development and metastasis Cell 2004 118 3 277-279 
Dunn LK Mohammad KS Fournier PG Hypoxia and TGF-&#946; drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment PLoS ONE 2009 4 9 e6896 
Katoh M Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGF&#946;, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors Int J Oncol 2010 36 2 415-420 
Shimo T Kubota S Yoshioka N Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research 2006 21 7 1045-1059 
Alarmo EL Kallioniemi A Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis? Endocr-Relat Cancer 2010 17 2 R123-R139 
Johnson RW Nguyen MP Padalecki SS TGF-&#946; promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling Cancer Res 2011 71 3 822-831 
Futakuchi M Nannuru KC Varney ML Transforming growth factor-&#946; signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation Cancer Sci 2009 100 1 71-81 
Bierie B Stover DG Abel TW Transforming growth factor-&#946; regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment Cancer Res 2008 68 6 1809-1819 
Korpal M Yan J Lu X Imaging transforming growth factor-&#946; signaling dynamics and therapeutic response in breast cancer bone metastasis Nat Med 2009 15 8 960-966 
Petersen M Pardali E Horst G Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis Oncogene 2010 29 9 1351-1361 
Buijs JT Que I Lowik CW Inhibition of bone resorption and growth of breast cancer in the bone microenvironment Bone 2009 44 2 380-386 
Buijs JT Henriquez NV Overveld PG TGF-&#946; and BMP7 interactions in tumour progression and bone metastasis Clin Exp Metastasis 2007 24 8 609-617 
Buijs JT Kuijpers CC Pluijm G Targeted therapy options for treatment of bone metastases; beyond bisphosphonates Curr Pharm Des 2010 16 27 3015-3027 
Buijs JT Petersen M Horst G Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis? Curr Pharm Des 2010 16 11 1291-1300 
Kingsley LA Fournier PG Chirgwin JM Molecular biology of bone metastasis Mol Cancer Ther 2007 6 10 2609-2617 
McMahon S Charbonneau M Grandmont S Transforming growth factor &#946;1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression J Biol Chem 2006 281 34 24171-24181 
Pluijm G Sijmons B Vloedgraven H Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research 2001 16 6 1077-1091 
Davies S Jiang WG ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis Anticancer Res 2010 30 4 1163-1168 
Galaup A Cazes A Jan S Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness Proc Natl Acad Sci USA 2006 103 49 18721-18726 
Gupta GP Perk J Acharyya S ID genes mediate tumor reinitiation during breast cancer lung metastasis Proc Natl Acad Sci USA 2007 104 49 19506-19511 
Sadej R Romanska H Kavanagh D Tetraspanin CD151 regulates transforming growth factor &#946; signaling: implication in tumor metastasis Cancer Res 2010 70 14 6059-6070 
Human Gene Mutation Database 2011 
Veiga-da-Cunha M Gerin I Chen YT A gene on chromosome 11q23 coding for a putative glucose-6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic Am J Hum Genet 1998 63 976-983 
Visser G Rake JP Fernandes J Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I J Pediatr 2000 137 187-191 
Weston BW Lin JU Muenzer J Glucose-6-Phosphatase Mutation G188R Confers an Atypical Glycogen Storage Disease Type 1b Phenotype Pediatr Res 2000 48 329-334 
Launay-Vacher V Deray G Hypertension and proteinuria: a class-effect of antiangiogenic therapies Anticancer Drugs. 2009 20 1 81-82 
Chowdhury S Spicer J Harper P Hypertension and targeted therapy: part 1. Bevacizumab Targeted Oncology. 2006 1 2 104-108 
Chowdhury S Spicer J Harper P Hypertension and targeted therapy: part 2. Small molecule inhibitors of VEGF Targeted Oncology. 2006 1 3 172-178 
Roodhart JM Langenberg MH Witteveen E The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway Curr Clin Pharmacol. 2008 3 2 132-143 
Humphreys BD Atkins MB Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res. 2009 15 19 5947-5949 
Rixe O Billemont B Izzedine H Hypertension as a predictive factor of sunitinib activity Ann Oncol. 2007 18 6 1117 
Yang R Thomas GR Bunting S Effects of vascular endothelial growth factor on hemodynamics and cardiac performance J Cardiovasc Pharmacol. 1996 27 6 838-844 
Wei W Jin H Chen ZW Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants J Cardiovasc Pharmacol. 2004 44 5 615-621 
Steeghs N Gelderblom H Roodt JO Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor Clin Cancer Res. 2008 14 11 3470-3476 
Dechend R Luft FC Angiogenesis factors and preeclampsia Nature Med. 2008 14 11 1187-1188 
Motzer RJ Hutson TE Tomczak P Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol. 2009 27 22 3584-3590 
Sunitinib malate (SUTENT&#174;) prescribing information. Revised July 2010 
Rini BI Schiller JH Fruehauf JP Association of diastolic blood pressure (dBP) &gt;= 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). Poster presentation at the 44th annual meeting of the American Society of Clinical Oncology. Chicago, IL. May 30, 2008 to June 3, 2008. Abstract 3543
Bono P Elfving H Utriainen T Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma Ann Oncol. 2009 20 2 393-394 
Dahlberg SE Sandler AB Brahmer JR Schiller JH Johnson DH Clinical course of advanced non&#8211;small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol. 2010 28 6 949-954 
Friberg G Kasza K Vokes EE Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G) J Clin Oncol. 2005 23 suppl 196s Abstract 3020
Scartozzi M Galizia E Chiorrini S Arterial hypertension correlates with clinical outcome in colorectal cancer patients with first-line bevacizumab Ann Oncol. 2009 20 2 227-230 
Gore ME Szczylik C Porta C Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Lancet Oncol. 2009 10 8 757-763 
Motzer RJ Michaelson MD Redman BG Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol. 2006 24 1 16-24 
Motzer RJ Rini BI Bukowski RM Sunitinib in patients with metastatic renal cell carcinoma JAMA. 2006 295 21 2516-2524 
Motzer RJ Hutson TE Tomczak P Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med. 2007 356 2 115-124 
Therasse P Arbuck SG Eisenhauer EA New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst. 2000 92 3 205-216 
Chobanian AV Bakris GL Black HR Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension. 2003 42 6 1206-1252 
Motzer RJ Bacik J Murphy BA Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma J Clin Oncol. 2002 20 1 289-296 
Heng DY Xie W Regan MM Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol. 2009 27 34 5794-5799 
Zhu X Stergiopoulos K Wu S Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol. 2009 48 1 9-17 
Launay-Vacher V Ayllon J Janus N Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma [published online ahead of print November 12, 2009] Urol Oncol 
Maitland ML Bakris GL Black HR Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst. 2010 102 9 596-604 
Langenberg MH van Herpen CM De Bono J Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors J Clin Oncol. 2009 27 36 6152-6159 
Bamias A Lainakis G Manios E Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib J Chemother. 2009 21 3 347-350 
Van Heeckeren WJ Ortiz J Cooney MM Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol. 2007 25 21 2993-2995 
Hood JD Meininger CJ Ziche M VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells Am J Physiol. 1998 274 3, pt 2 H1054-H1058 
van der Veldt AA de Boer MP Boven E Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib Anticancer Drugs. 2010 21 4 439-446 
Houk BE Bello CL Poland B Rosen LS Demetri GD Motzer RJ Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol. 2010 66 2 357-371 
Agaisse H Petersen UM Boutros M Mathey-Prevot B Perrimon N Signaling role of hemocytes in Drosophila JAK/STAT-dependent response to septic injury Dev Cell 2003 5 441-450 
Almudi I Stocker H Hafen E Corominas M Serras F SOCS36E specifically interferes with Sevenless signaling during Drosophila eye development Dev Biol 2009 326 212-223 
Amsen D Blander JM Lee GR Tanigaki K Honjo T Flavell RA Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells Cell 2004 117 515-526 
Arbouzova NI Zeidler MP JAK/STAT signalling in Drosophila: insights into conserved regulatory and cellular functions Development 2006 133 2605-2616 
Asano H Aonuma M Sanosaka T Kohyama J Namihira M Nakashima K Astrocyte differentiation of neural precursor cells is enhanced by retinoic acid through a change in epigenetic modification Stem Cells 2009 27 2744-2752 
Babst M Katzmann DJ Snyder WB Wendland B Emr SD Endosome-associated complex, ESCRT-II, recruits transport machinery for protein sorting at the multivesicular body Dev Cell 2002 3 283-289 
Bach EA Vincent S Zeidler MP Perrimon N A sensitized genetic screen to identify novel regulators and components of the Drosophila janus kinase/signal transducer and activator of transcription pathway Genetics 2003 165 1149-1166 
Bach EA Ekas LA Ayala-Camargo A Flaherty MS Lee H Perrimon N Baeg GH GFP reporters detect the activation of the Drosophila JAK/STAT pathway in vivo Gene Expr Patterns 2007 7 323-331 
Baonza A Freeman M Notch signalling and the initiation of neural development in the Drosophila eye Development 2001 128 3889-3898 
Baonza A Freeman M Control of Drosophila eye specification by Wingless signalling Development 2002 129 5313-5322 
Betz A Lampen N Martinek S Young MW Darnell JE Jr A Drosophila PIAS homologue negatively regulates stat92E Proc Natl Acad Sci U S A 2001 98 9563-9568 
Binari R Perrimon N Stripe-specific regulation of pair-rule genes by hopscotch, a putative Jak family tyrosine kinase in Drosophila Genes Dev 1994 8 300-312 
Bishop N Woodman P TSG101/mammalian VPS23 and mammalian VPS28 interact directly and are recruited to VPS4-induced endosomes J Biol Chem 2001 276 11735-11742 
Bonni A Sun Y Nadal-Vicens M Bhatt A Frank DA Rozovsky I Stahl N Yancopoulos GD Greenberg ME Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway Science 1997 278 477-483 
Boulay JL O'Shea JJ Paul WE Molecular phylogeny within type I cytokines and their cognate receptors Immunity 2003 19 159-163 
Bowman T Garcia R Turkson J Jove R STATs in oncogenesis Oncogene 2000 19 2474-2488 
Bromberg JF Wrzeszczynska MH Devgan G Zhao Y Pestell RG Albanese C Darnell JE Jr Stat3 as an oncogene Cell 1999 98 295-303 
Brown S Hu N Hombria JC Identification of the first invertebrate interleukin JAK/STAT receptor, the Drosophila gene domeless Curr Biol 2001 11 1700-1705 
Brown S Zeidler MP Unphosphorylated STATs go nuclear Curr Opin Genet Dev 2008 18 455-460 
Calo V Migliavacca M Bazan V Macaluso M Buscemi M Gebbia N Russo A STAT proteins: from normal control of cellular events to tumorigenesis J Cell Physiol 2003 197 157-168 
Cavodeassi F Diez Del Corral R Campuzano S Dominguez M Compartments and organising boundaries in the Drosophila eye: the role of the homeodomain Iroquois proteins Development 1999 126 4933-4942 
Chanut F Heberlein U Role of the morphogenetic furrow in establishing polarity in the Drosophila eye Development 1995 121 4085-4094 
Chao JL Tsai YC Chiu SJ Sun YH Localized Notch signal acts through eyg and upd to promote global growth in Drosophila eye Development 2004 131 3839-3847 
Cho KO Chern J Izaddoost S Choi KW Novel signaling from the peripodial membrane is essential for eye disc patterning in Drosophila Cell 2000 103 331-342 
Christova R Jones T Wu PJ Bolzer A Costa-Pereira AP Watling D Kerr IM Sheer D P-STAT1 mediates higher-order chromatin remodelling of the human MHC in response to IFNgamma J Cell Sci 2007 120 3262-3270 
Chung CD Liao J Liu B Rao X Jay P Berta P Shuai K Specific inhibition of Stat3 signal transduction by PIAS3 Science 1997 278 1803-1805 
Classen AK Bunker BD Harvey KF Vaccari T Bilder D A tumor suppressor activity of Drosophila Polycomb genes mediated by JAK-STAT signaling Nat Genet 2009 41 1150-1155 
Constantinescu SN Girardot M Pecquet C Mining for JAK-STAT mutations in cancer Trends Biochem Sci 2008 33 122-131 
Croker BA Kiu H Nicholson SE SOCS regulation of the JAK/STAT signalling pathway Semin Cell Dev Biol 2008 19 414-422 
D'Costa A Reifegerste R Sierra S Moses K The Drosophila ramshackle gene encodes a chromatin-associated protein required for cell morphology in the developing eye Mech Dev 2006 123 591-604 
de la Iglesia N Konopka G Puram SV Chan JA Bachoo RM You MJ Levy DE Depinho RA Bonni A Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway Genes Dev 2008 22 449-462 
Devergne O Ghiglione C Noselli S The endocytic control of JAK/STAT signalling in Drosophila J Cell Sci 2007 120 3457-3464 
Dominguez M de Celis JF A dorsal/ventral boundary established by Notch controls growth and polarity in the Drosophila eye Nature 1998 396 276-278 
Dominguez M Ferres-Marco D Gutierrez-Avino FJ Speicher SA Beneyto M Growth and specification of the eye are controlled independently by Eyegone and Eyeless in Drosophila melanogaster Nat Genet 2004 36 31-39 
Ekas LA Baeg GH Flaherty MS Ayala-Camargo A Bach EA JAK/STAT signaling promotes regional specification by negatively regulating wingless expression in Drosophila Development 2006 133 4721-4729 
Faivre S Kroemer G Raymond E Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov 2006 5 671-688 
Flaherty MS Zavadil J Ekas LA Bach EA Genome-wide expression profiling in the Drosophila eye reveals unexpected repression of notch signaling by the JAK/STAT pathway Dev Dyn 2009 238 2235-2253 
Fonseca BD Smith EM Lee VH MacKintosh C Proud CG PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex J Biol Chem 2007 282 24514-24524 
Fu W Baker NE Deciphering synergistic and redundant roles of Hedgehog, Decapentaplegic and Delta that drive the wave of differentiation in Drosophila eye development Development 2003 130 5229-5239 
Ghiglione C Devergne O Georgenthum E Carballes F Medioni C Cerezo D Noselli S The Drosophila cytokine receptor Domeless controls border cell migration and epithelial polarization during oogenesis Development 2002 129 5437-5447 
Gilbert MM Weaver BK Gergen JP Reich NC A novel functional activator of the Drosophila JAK/STAT pathway, unpaired2, is revealed by an in vivo reporter of pathway activation Mech Dev 2005 122 939-948 
Gilbert MM Beam CK Robinson BS Moberg KH Genetic interactions between the Drosophila tumor suppressor gene ept and the stat92E transcription factor PLoS One 2009 4 e7083 
Go MJ Eastman DS Artavanis-Tsakonas S Cell proliferation control by Notch signaling in Drosophila development Development 1998 125 2031-2040 
Greenwood S Struhl G Progression of the morphogenetic furrow in the Drosophila eye: the roles of Hedgehog, Decapentaplegic and the Raf pathway Development 1999 126 5795-5808 
Gutierrez-Avino FJ Ferres-Marco D Dominguez M The position and function of the Notch-mediated eye growth organizer: the roles of JAK/STAT and four-jointed EMBO Rep 2009 10 1051-1058 
Hanahan D Weinberg RA The hallmarks of cancer Cell 2000 100 57-70 
Hanratty WP Dearolf CR The Drosophila Tumorous-lethal hematopoietic oncogene is a dominant mutation in the hopscotch locus Mol Gen Genet 1993 238 33-37 
Hari KL Cook KR Karpen GH The Drosophila Su(var)2-10 locus regulates chromosome structure and function and encodes a member of the PIAS protein family Genes Dev 2001 15 1334-1348 
Harrison DA Binari R Nahreini TS Gilman M Perrimon N Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects EMBO J 1995 14 2857-2865 
Harrison DA McCoon PE Binari R Gilman M Perrimon N Drosophila unpaired encodes a secreted protein that activates the JAK signaling pathway Genes Dev 1998 12 3252-3263 
Hauck B Gehring WJ Walldorf U Functional analysis of an eye specific enhancer of the eyeless gene in Drosophila Proc Natl Acad Sci U S A 1999 96 564-569 
Hay BA Wolff T Rubin GM Expression of baculovirus P35 prevents cell death in Drosophila Development 1994 120 2121-2129 
Heberlein U Wolff T Rubin GM The TGF beta homolog dpp and the segment polarity gene hedgehog are required for propagation of a morphogenetic wave in the Drosophila retina Cell 1993 75 913-926 
Hennig KM Neufeld TP Inhibition of cellular growth and proliferation by dTOR overexpression in Drosophila Genesis 2002 34 107-110 
Heppner GH Tumor heterogeneity Cancer Res 1984 44 2259-2265 
Heslip TR Theisen H Walker H Marsh JL Shaggy and dishevelled exert opposite effects on Wingless and Decapentaplegic expression and on positional identity in imaginal discs Development 1997 124 1069-1078 
Hombria JC Brown S The fertile field of Drosophila Jak/STAT signalling Curr Biol 2002 12 R569-R575 
Hombria JC Brown S Hader S Zeidler MP Characterisation of Upd2, a Drosophila JAK/STAT pathway ligand Dev Biol 2005 288 420-433 
Hou XS Melnick MB Perrimon N Marelle acts downstream of the Drosophila HOP/JAK kinase and encodes a protein similar to the mammalian STATs Cell 1996 84 411-419 
Hou SX Zheng Z Chen X Perrimon N The Jak/STAT pathway in model organisms: emerging roles in cell movement Dev Cell 2002 3 765-778 
Huang H Rambaldi I Daniels E Featherstone M Expression of the Wdr9 gene and protein products during mouse development Dev Dyn 2003 227 608-614 
Ingham PW McMahon AP Hedgehog signaling in animal development: paradigms and principles Genes Dev 2001 15 3059-3087 
Jang CC Chao JL Jones N Yao LC Bessarab DA Kuo YM Jun S Desplan C Beckendorf SK Sun YH Two Pax genes, eye gone and eyeless, act cooperatively in promoting Drosophila eye development Development 2003 130 2939-2951 
Karsten P Hader S Zeidler MP Cloning and expression of Drosophila SOCS36E and its potential regulation by the JAK/STAT pathway Mech Dev 2002 117 343-346 
Karsten P Plischke I Perrimon N Zeidler MP Mutational analysis reveals separable DNA binding and trans-activation of Drosophila STAT 92E Cell Signal 2006 18 819-829 
Kile BT Alexander WS The suppressors of cytokine signalling (SOCS) Cell Mol Life Sci 2001 58 1627-1635 
Kinzler KW Vogelstein B Lessons from hereditary colorectal cancer Cell 1996 87 159-170 
Kisseleva T Bhattacharya S Braunstein J Schindler CW Signaling through the JAK/STAT pathway, recent advances and future challenges Gene 2002 285 1-24 
Klebes A Knust E A conserved motif in Crumbs is required for E-cadherin localisation and zonula adherens formation in Drosophila Curr Biol 2000 10 76-85 
Krebs DL Hilton DJ SOCS proteins: negative regulators of cytokine signaling Stem Cells 2001 19 378-387 
Kurata S Go MJ Artavanis-Tsakonas S Gehring WJ Notch signaling and the determination of appendage identity Proc Natl Acad Sci USA 2000 97 2117-2122 
Kurooka H Honjo T Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5 J Biol Chem 2000 275 17211-17220 
Langer JA Cutrone EC Kotenko S The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions Cytokine Growth Factor Rev 2004 15 33-48 
Lee T Luo L Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis Neuron 1999 22 451-461 
Leong KG Karsan A Recent insights into the role of Notch signaling in tumorigenesis Blood 2006 107 2223-2233 
Levy DE Darnell JE Jr Stats: transcriptional control and biological impact Nat Rev Mol Cell Biol 2002 3 651-662 
Li WX Canonical and non-canonical JAK-STAT signaling Trends Cell Biol 2008 18 545-551 
Liu B Liao J Rao X Kushner SA Chung CD Chang DD Shuai K Inhibition of Stat1-mediated gene activation by PIAS1 Proc Natl Acad Sci U S A 1998 95 10626-10631 
Lovegrove B Simoes S Rivas ML Sotillos S Johnson K Knust E Jacinto A Hombria JC Coordinated control of cell adhesion, polarity, and cytoskeleton underlies Hox-induced organogenesis in Drosophila Curr Biol 2006 16 2206-2216 
Lu Y Fukuyama S Yoshida R Kobayashi T Saeki K Shiraishi H Yoshimura A Takaesu G Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic J Biol Chem 2006 281 36683-36690 
Luo H Hanratty WP Dearolf CR An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects EMBO J 1995 14 1412-1420 
Luo H Asha H Kockel L Parke T Mlodzik M Dearolf CR The Drosophila Jak kinase hopscotch is required for multiple developmental processes in the eye Dev Biol 1999 213 432-441 
Ma C Moses K Wingless and patched are negative regulators of the morphogenetic furrow and can affect tissue polarity in the developing Drosophila compound eye Development 1995 121 2279-2289 
Ma C Zhou Y Beachy PA Moses K The segment polarity gene hedgehog is required for progression of the morphogenetic furrow in the developing Drosophila eye Cell 1993 75 927-938 
Martinez AM Schuettengruber B Sakr S Janic A Gonzalez C Cavalli G Polyhomeotic has a tumor suppressor activity mediated by repression of Notch signaling Nat Genet 2009 41 1076-1082 
McNeill H Yang CH Brodsky M Ungos J Simon MA mirror encodes a novel PBX-class homeoprotein that functions in the definition of the dorsal-ventral border in the Drosophila eye Genes Dev 1997 11 1073-1082 
Moberg KH Schelble S Burdick SK Hariharan IK Mutations in erupted, the Drosophila ortholog of mammalian tumor susceptibility gene 101, elicit non-cell-autonomous overgrowth Dev Cell 2005 9 699-710 
Mukherjee T Hombria JC Zeidler MP Opposing roles for Drosophila JAK/STAT signalling during cellular proliferation Oncogene 2005 24 2503-2511 
Mukherjee T Schafer U Zeidler MP Identification of Drosophila genes modulating janus kinase/signal transducer and activator of transcription signal transduction Genetics 2006 172 1683-1697 
Muller P Kuttenkeuler D Gesellchen V Zeidler MP Boutros M Identification of JAK/STAT signalling components by genome-wide RNA interference Nature 2005 436 871-875 
Nosaka T Kawashima T Misawa K Ikuta K Mui AL Kitamura T STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells EMBO J 1999 18 4754-4765 
Oldham S Hafen E Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control Trends Cell Biol 2003 13 79-85 
Papayannopoulos V Tomlinson A Panin VM Rauskolb C Irvine KD Dorsal-ventral signaling in the Drosophila eye Science 1998 281 2031-2034 
Patterson SG Wei S Chen X Sallman DA Gilvary DL Zhong B Pow-Sang J Yeatman T Djeu JY Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells Oncogene 2006 25 6113-6122 
Perrimon N Mahowald AP l(1)hopscotch, A larval-pupal zygotic lethal with a specific maternal effect on segmentation in Drosophila Dev Biol 1986 118 28-41 
Ramos VC Vidal-Taboada J Bergonon S Egeo A Fisher EM Scartezzini P Oliva R Characterisation and expression analysis of the WDR9 gene, located in the Down critical region-2 of the human chromosome 21 Biochim Biophys Acta 2002 1577 377-383 
Ready DF Hanson TE Benzer S Development of the Drosophila retina, a neurocrystalline lattice Dev Biol 1976 53 217-240 
Reifegerste R Ma C Moses K A polarity field is established early in the development of the Drosophila compound eye Mech Dev 1997 68 69-79 
Reynolds-Kenneally J Mlodzik M Notch signaling controls proliferation through cell-autonomous and non-autonomous mechanisms in the Drosophila eye Dev Biol 2005 285 38-48 
Royet J Finkelstein R hedgehog, wingless and orthodenticle specify adult head development in Drosophila Development 1996 122 1849-1858 
Sancak Y Thoreen CC Peterson TR Lindquist RA Kang SA Spooner E Carr SA Sabatini DM PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase Mol Cell 2007 25 903-915 
Schindler C Levy DE Decker T JAK-STAT signaling: from interferons to cytokines J Biol Chem 2007 282 20059-20063 
Schwartz YB Pirrotta V Polycomb silencing mechanisms and the management of genomic programmes Nat Rev Genet 2007 8 9-22 
Shi S Calhoun HC Xia F Li J Le L Li WX JAK signaling globally counteracts heterochromatic gene silencing Nat Genet 2006 38 1071-1076 
Shi M Lin TH Appell KC Berg LJ Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation Immunity 2008a 28 763-773 
Shi S Larson K Guo D Lim SJ Dutta P Yan SJ Li WX Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability Nat Cell Biol 2008b 10 489-496 
Shuai K Regulation of cytokine signaling pathways by PIAS proteins Cell Res 2006 16 196-202 
Smirnova OV Ostroukhova TY Bogorad RL JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? World J Gastroenterol 2007 13 6478-6491 
Song MR Ghosh A FGF2-induced chromatin remodeling regulates CNTF-mediated gene expression and astrocyte differentiation Nat Neurosci 2004 7 229-235 
Sotillos S Diaz-Meco MT Caminero E Moscat J Campuzano S DaPKC-dependent phosphorylation of Crumbs is required for epithelial cell polarity in Drosophila J Cell Biol 2004 166 549-557 
Sparmann A van Lohuizen M Polycomb silencers control cell fate, development and cancer Nat Rev Cancer 2006 6 846-856 
Staehling-Hampton K Jackson PD Clark MJ Brand AH Hoffmann FM Specificity of bone morphogenetic protein-related factors: cell fate and gene expression changes in Drosophila embryos induced by decapentaplegic but not 60A Cell Growth Differ 1994 5 585-593 
Stephanou A Latchman DS Opposing actions of STAT-1 and STAT-3 Growth Factors 2005 23 177-182 
Subramaniam PS Torres BA Johnson HM So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors Cytokine 2001 15 175-187 
Takizawa T Nakashima K Namihira M Ochiai W Uemura A Yanagisawa M Fujita N Nakao M Taga T DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain Dev Cell 2001 1 749-758 
Tepass U Theres C Knust E crumbs encodes an EGF-like protein expressed on apical membranes of Drosophila epithelial cells and required for organization of epithelia Cell 1990 61 787-799 
Thompson BJ Mathieu J Sung HH Loeser E Rorth P Cohen SM Tumor suppressor properties of the ESCRT-II complex component Vps25 in Drosophila Dev Cell 2005 9 711-720 
Timofeeva OA Plisov S Evseev AA Peng S Jose-Kampfner M Lovvorn HN Dome JS Perantoni AO Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis Oncogene 2006 25 7555-7564 
Treisman JE Rubin GM wingless inhibits morphogenetic furrow movement in the Drosophila eye disc Development 1995 121 3519-3527 
Tsai YC Sun YH Long-range effect of upd, a ligand for Jak/STAT pathway, on cell cycle in Drosophila eye development Genesis 2004 39 141-153 
Tsai YC Yao JG Chen PH Posakony JW Barolo S Kim J Sun YH Upd/Jak/STAT signaling represses wg transcription to allow initiation of morphogenetic furrow in Drosophila eye development Dev Biol 2007 306 760-771 
Ungureanu D Vanhatupa S Kotaja N Yang J Aittomaki S Janne OA Palvimo JJ Silvennoinen O PIAS proteins promote SUMO-1 conjugation to STAT1 Blood 2003 102 3311-3313 
Vaccari T Bilder D The Drosophila tumor suppressor vps25 prevents nonautonomous overproliferation by regulating notch trafficking Dev Cell 2005 9 687-698 
Vander Haar E Lee SI Bandhakavi S Griffin TJ Kim DH Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 Nat Cell Biol 2007 9 316-323 
Wang YH Huang ML Reduction of Lobe leads to TORC1 hypoactivation that induces ectopic Jak/STAT signaling to impair Drosophila eye development Mech Dev 2009 126 781-790 
Weichhart T Costantino G Poglitsch M Rosner M Zeyda M Stuhlmeier KM Kolbe T Stulnig TM Horl WH Hengstschlager M Muller M Saemann MD The TSC-mTOR signaling pathway regulates the innate inflammatory response Immunity 2008 29 565-577 
Wicking C McGlinn E The role of hedgehog signalling in tumorigenesis Cancer Lett 2001 173 1-7 
Williams JG STAT signalling in cell proliferation and in development Curr Opin Genet Dev 2000 10 503-507 
Wolff T Ready DF The beginning of pattern formation in the Drosophila compound eye: the morphogenetic furrow and the second mitotic wave Development 1991 113 841-850 
Xu T Rubin GM Analysis of genetic mosaics in developing and adult Drosophila tissues Development 1993 117 1223-1237 
Yan R Small S Desplan C Dearolf CR Darnell JE Jr Identification of a Stat gene that functions in Drosophila development Cell 1996 84 421-430 
Zeidler MP Perrimon N Strutt DI Polarity determination in the Drosophila eye: a novel role for unpaired and JAK/STAT signaling Genes Dev 1999 13 1342-1353 
Proper KI Hildebrandt VH Van der Beek AJ Twisk JW Van Mechelen W Effect of individual counseling on physical activity fitness and health: a randomized controlled trial in a workplace setting Am J Prev Med 4 2003 24 3 218-226 
Church TS Martin CK Thompson AM Earnest CP Mikus CR Blair SN Changes in weight, waist circumference and compensatory responses with different doses of exercise among sedentary, overweight postmenopausal women PLoS One 2009 4 2 e4515 
Fairey AS Courneya KS Field CJ Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial Brain Behav Immun 2005 19 5 381-388 
Kasapis C Thompson PD The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review J Am Coll Cardiol 2005 45 10 1563-1569 
Lokey EA Tran ZV Effects of exercise training on serum lipid and lipoprotein concentrations in women: a meta-analysis Int J Sports Med 1989 10 6 424-429 
2008 physical activity guidelines for Americans [Updated 4 November 2009]. Available from:
Greenland P Knoll MD Stamler J Major risk factors as antecedents of fatal and nonfatal coronary heart disease events JAMA 2003 290 7 891-897 
Bild DE Folsom AR Lowe LP Prevalence and correlates of coronary calcification in black and white young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study Arterioscler Thromb Vasc Biol 2001 21 5 852-857 
Blair SN Kampert JB Kohl HW Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women JAMA 1996 276 3 205-210 
Tuomilehto J Rastenyte D Jousilahti P Sarti C Vartiainen E Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population Stroke 1996 27 2 210-215 
Wolf PA D&#8217;Agostino RB Belanger AJ Kannel WB Probability of stroke: a risk profile from the Framingham Study Stroke 1991 22 3 312-318 
Tudor-Locke C Bell RC Myers AM Controlled outcome evaluation of the First Step Program: a daily physical activity intervention for individuals with type II diabetes Int J Obes Relat Metab Disord 2004 28 1 113-119 
Ash S Reeves M Bauer J A randomised control trial comparing lifestyle groups, individual counselling and written information in the management of weight and health outcomes over 12 months Int J Obes(Lond) 2006 30 10 1557-1564 
Carr LJ Bartee RT Dorozynski C Broomfield JF Smith ML Smith DT Internet-delivered behavior change program increases physical activity and improves cardiometabolic disease risk factors in sedentary adults: results of a randomized controlled trial Prev Med 2008 46 5 431-438 
Norman GJ Zabinski MF Adams MA Rosenberg DE Yaroch AL Atienza AA A review of eHealth interventions for physical activity and dietary behavior change Am J Prev Med 2007 33 4 336-345 
De Greef K Deforche B Tudor-Locke C De Bourdeaudhuij I A cognitive-behavioural pedometer-based group intervention on physical activity and sedentary behaviour in individuals with type 2 diabetes Health Educ Res 2010 25 5 724-736 
Baker G Gray SR Wright A The effect of a pedometer-based community walking intervention &#8220;Walking for Wellbeing in the West&#8221; on physical activity levels and health outcomes: a 12-week randomized controlled trial Int J Behav Nutr Phys Act 2010 7 1 51 
Polzien KM Jakicic JM Tate DF Otto AD The efficacy of a technology-based system in a short-term behavioral weight loss intervention Obesity 2007 15 4 825-830 
Bravata DM Smith-Spangler C Sundaram V Using pedometers to increase physical activity and improve health: a systematic review JAMA 2007 298 19 2296-2304 
Stefanick ML Physical activity for preventing and treating obesity-related dyslipoproteinemias Med Sci Sports Exerc 1999 31 11 Suppl S609-S618 
Barry VW McClain AC Shuger S Using a technology-based intervention to promote weight loss in sedentary overweight or obese adults: a randomized controlled trial study design Diabetes Metab Syndr Obes 2011 4 67-77 
Sharma M Behavioural interventions for preventing and treating obesity in adults Obes Rev 2007 8 5 441-449 
Clark MM Niaura R King TK Pera V Depression, smoking, activity level, and health status: pretreatment predictors of attrition in obesity treatment Addict Behav 1996 21 4 509-513 
Chobanian AV Bakris GL Black HR The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 2003 289 19 2560-2572 
Blair S Dunn A Marcus B Carpenter R Active Living Every Day: 20 weeks to lifelong vitality Champaign Human Kinetics 2001 
Carpenter R Finley C Healthy Eating Every Day Champaign Human Kinetics 2005 
Prochaska JO Norcross JC DiClemente CC Changing for good: A revolutionary six-stage program for overcoming bad habits and moving your life positively forward New York, NY Avon Books Inc. 1994 
Bandura A Social foundations of thought and action: A social cognitive theory Englewood Cliffs, NJ Prentice Hall 1986 
Albright A Franz M Hornsby G American College of Sports Medicine position stand. Exercise and type 2 diabetes Med Sci Sports Exerc 2000 32 7 1345-1360 
Butryn ML Phelan S Hill JO Wing RR Consistent self-monitoring of weight: a key component of successful weight loss maintenance Obesity(Silver Spring) 2007 15 12 3091-3096 
van Baak MA Borghouts LB Relationships with physical activity Nutr Rev 2000 58 3 Pt 2 S16-S18 
Borghouts LB Keizer HA Exercise and insulin sensitivity: a review Int J Sports Med 2000 21 1 1-12 
Kraniou GN Cameron-Smith D Hargreaves M Effect of short-term training on GLUT-4 mRNA and protein expression in human skeletal muscle Exp Physiol 2004 89 5 559-563 
Ren JM Semenkovich CF Gulve EA Gao J Holloszy JO Exercise induces rapid increases in GLUT4 expression, glucose transport capacity, and insulin-stimulated glycogen storage in muscle J Biol Chem 1994 269 20 14396-14401 
Anderson JW Konz EC Obesity and disease management: effects of weight loss on comorbid conditions Obes Res 2001 9 Suppl 4 326S-334S 
Blumenthal JA Sherwood A Gullette ECD Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning Arch Intern Med 2000 160 13 1947-1958 
Bytzer P. Talley N.J. Leemon M. Young L.J. Jones M.P. Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults Arch Intern Med. 2001 161 1989-1996 
Ricci J.A. Siddique R. Stewart W.F. Sandler R.S. Sloan S. Farup C.E. Upper gastrointestinal symptoms in a US national sample of adults with diabetes Scand J Gastroenterol. 2000 35 152-159 
Samsom M. Bharucha A. Gerich J.E. Diabetes mellitus and gastric emptying: questions and issues in clinical practice Diabetes Metab Res Rev. 2009 25 502-514 
Patrick A. Epstein O. Review article: gastroparesis Aliment Pharmacol Ther. 2008 27 724-740 
Frank J.W. Saslow S.B. Camilleri M. Thomforde G.M. Dinneen S. Rizza R.A. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus Gastroenterology 1995 109 755-765 
Intagliata N. Koch K.L. Gastroparesis in type 2 diabetes mellitus: prevalence, etiology, diagnosis, and treatment Curr Gastroenterol Rep. 2007 9 270-279 
Barnett J.L. Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility Gastroenterology 1988 94 739-744 
Lysy J. Israeli E. Strauss-Liviatan N. Goldin E. Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients Neurogastroenterol Motil. 2006 18 433-440 
Horowitz M. Jones K.L. Rayner C.K. Read N.W. &#8220;Gastric&#8221; hypoglycaemia &#8212; an important concept in diabetes management Neurogastroenterol Motil. 2006 18 405-407 
Ma J. Rayner C.K. Jones K.L. Horowitz M. Diabetic gastroparesis: diagnosis and management Drugs 2009 69 971-986 
Hejazi R. McCallum R. Diabetic gastroparesis: a review of medical treatments Pract Gastroenterol. 2009 6 10-20 
Forster J. Damjanov I. Lin Z. Sarosiek I. Wetzel P. McCallum R.W. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings J Gastrointest Surg. 2005 9 102-108 
Lin Z. Sarosiek I. Forster J. Damjanov I. Hou Q. McCallum R.W. Association of the status of interstitial cells of Cajal and electrogastrogram parameters, gastric emptying and symptoms in patients with gastroparesis Neurogastroenterol Motil. 2009 22 56-61 
Pasricha P.J. Pehlivanov N. Sugumar A. Jankovic J. Drug insight: from disturbed motility to disordered movement: a review of the clinical benefits and medicolegal risks of metoclopramide Nat Clin Pract Gastroenterol Hepatol. 2006 3 138-148 
Fraser R.J. Horowitz M. Maddox A.F. Harding P.E. Chatterton B.E. Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin.dependent) diabetes mellitus Diabetologia 1990 33 675-680 
Sogabe M. Okahisa T. Tsujigami K. Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control J Gastroenterol. 2005 40 583-590 
Schvarcz E. Palm&#233;r M. Aman J. Lindkvist B. Beckman K.W. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus Diabetic Med. 1993 10 660-663 
Schvarcz E. Palm&#233;r M. Aman J. Berne C. Hypoglycemia increases the gastric emptying rate in healthy subjects Diabetes Care 1995 18 674-676 
Miller G. Palmer K.R. Smith B. Ferrington C. Merrick M.V. Smoking delays gastric emptying of solids Gut 1989 30 50-53 
Jones K.L. Russo A. Stevens J.E. Wishart J.M. Berry M.K. Horowitz M. Predictors of delayed gastric emptying in diabetes Diabetes Care 2001 24 1264-1269 
Abell T.L. Camilleri M. Donohoe K. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine J Nucl Med Technol. 2008 36 44-54 
Eliasson B. Bj&#246;rnsson E. Urbanavicius V. Hyperinsulinaemia impairs gastrointestinal motility and slows carbohydrate absorption Diabetologia 1995 38 79-85 
Watkins C.C. Sawa A. Jaffrey S. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy J Clin Invest. 2000 106 373-384 
Bunck M.C. Diamant M. Corn&#233;r A. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial Diabetes Care 2009 32 762-768 
Heine R.J. Gaal L.F. Johns D. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial Ann Intern Med. 2005 143 559-569 
Little T.J. Pilichiewicz A.N. Russo A. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses J Clin Endocrinol Metab. 2006 91 1916-1923 
Vella A. Lee J.S. Camilleri M. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus Neurogastroenterol Motil. 2002 14 123-131 
Samsom M. Szarka L.A. Camilleri M. Vella A. Zinsmeister A.R. Rizza R.A. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition Am J Physiol Gastrointest Liver Physiol. 2000 278 946-951 
Koch C.A. Uwaifo G.I. Are gastrointestinal symptoms related to diabetes mellitus and glycemic control? Eur J Gastroenterol Hepatol. 2008 20 822-825 
Heine R.J. Brodows R. Diabetic gastroparesis N Engl J Med. 2007 357 418-420 
Longstreth G.F. Malagelada J.R. Kelly K.A. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis Ann Intern Med. 1977 86 195-196 
Perkel M.S. Moore C. Hersh T. Davidson E.D. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study Dig Dis Sci. 1979 24 662-666 
Peringer E. Jenner P. Marsden C.D. Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5-hydroxytryptamine J Pharm Pharmacol. 1975 27 442-444 
Koch K. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and tretment Dig Dis Sci. 1999 44 1061-1075 
Schade R.R. Dugas M.C. Lhotsky D.M. Gavaler J.S. Thiel D.H. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis Dig Dis Sci. 1985 30 10-15 
Erbas T. Varoglu E. Erbas B. Tastekin G. Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis Diabetes Care 1993 16 1511-1514 
McCallum R.W. Ricci D.A. Rakatansky H. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis Diabetes Care 1983 6 463-467 
Ricci D.A. Saltzman M.B. Meyer C. Callachan C. McCallum R.W. Effect of metoclopramide in diabetic gastroparesis J Clin Gastroenterol. 1985 7 25-32 
Snape W.J. Jr. Battle W.M. Schwartz S.S. Braunstein S.N. Goldstein H.A. Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus Ann Intern Med. 1982 96 444-446 
Talley N. Diabetic gastropathy and prokinetics Am J Gastroenterol. 2003 98 264-271 
Tonini M. Cipolina L. Poluuzzi E. Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics Aliment Pharmacol Ther. 2004 19 379-390 
Parkman H.P. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis Gastroenterology 2004 127 1592-1622 
Patterson D. Abell T. Rothstein R. Koch K. Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis Am J Gastroenterol. 1999 94 1230-1234 
Farup C.E. Leidy N.K. Murray M. Williams G.R. Helbers L. Quigley E.M. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis Diabetes Care 1998 21 1699-1706 
Heer M. Muller-Duysing W. Benes I. Diabetic gastroparesis: treatment with domperidone &#8212; a double-blind, placebo-controlled trial Digestion 1983 27 214-217 
Champion E.A. Domperidone (Motilium) improves symptoms and solid phase gastric emptying in diabetic gastroparesis Gastroenterol. 1987 82 975 
Dumitrascu D.L. Weinbeck M. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis Am J Gastroenterol. 2000 95 316-317 
Sugumar A. Singh A. Pasricha P.J. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis Clin Gastroenterol Hepatol. 2008 6 726-733 
Camilleri M. Clinical practice. Diabetic gastroparesis N Engl J Med. 2007 356 820-829 
Richards R.D. Davenport K. McCallum R.W. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin Am J Gastroenterol. 1993 88 203-207 
Janssens J. Peeters T.L. Vantrappen G. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies N Engl J Med. 1990 322 1028-1031 
Dive A. Miesse C. Galanti L. Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study Crit Care Med. 1995 23 1356-1362 
Talley N.J. Verlinden M. Geenen D.J. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial Gut 2001 49 395-401 
Talley N.J. Verlinden M. Snape W. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial Aliment Pharmacol Ther. 2000 14 1653-1661 
McCallum R.W. Cynshi O. Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis &#8212; a randomized, multicentre, placebo-controlled study Aliment Pharmacol Ther. 2007 26 1121-1130 
Hawkyard C.V. Koerner R.J. The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks J Antimicrob Chemother. 2007 59 347-358 
McCallum R.W. Prakash C. Campoli-Richards D.M. Goa K.L. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal disorders Drugs 1988 36 652-681 
Champion M.C. Management of idiopathic, diabetic and miscellaneous gastroparesis with cisapride Scand J Gastroenterol Suppl. 1989 165 44-52 
Horowitz M. Maddern G.J. Maddox A. Wishart J. Chatterton B.E. Shearman D.J. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis Gastroenterology 1987 93 311-315 
Horowitz M. Maddox A. Harding P.E. Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus Gastroenterology 1987 92 1899-1907 
McHugh S. Lico S. Diamant N.E. Cisapride vs. metoclopramide Dig Dis Sci. 1992 37 997-1001 
Havelund T. Oster-J&#248;rgensen E. Esh&#248;j O. Larsen M.L. Lauritsen K. Effects of cisapride on gastroparesis in patients with insulin-dependent diabetes mellitus Acta Medica Scandinavica 1987 222 339-343 
Takaya K. Ariyasu H. Kanamoto N. Ghrelin strongly stimulates growth hormone release in humans J Clin Endocrinol Metab. 2000 85 4908-4911 
Peino R. Baldelli R. Rodriguez-Garcia J. Ghrelin-induced growth hormone secretion in humans Eur J Endocrinol. 2000 143 R11-R14 
Date Y. Kojima M. Hosoda H. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans Endocrinology 2000 141 4255-4261 
Kojima M. Hosoda H. Date Y. Nakazato M. Matsuo H. Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach Nature 1999 402 656-660 
Howard A.D. Feighner S.D. Cully D.F. A receptor in pituitary and hypothalamus that functions in growth hormone release Science 1996 273 974-977 
Tack J. Depoortere I. Bisschops R. Influence of ghrelin on interdigestive gastrointestinal motility in humans Gut 2006 55 327-333 
Wren A.M. Seal L.J. Cohen M.A. Ghrelin enhances appetite and increases food intake in humans J Clin Endocrinol Metab. 2001 86 5992 
Druce M.R. Ghrelin increases food intake in obese as well as lean subjects Int J Obes (Lond). 2005 29 1130-1136 
Strasser F. Lutz T.A. Maeder M.T. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study Br J Cancer 2008 98 300-308 
Murray C.D. Martin N.M. Patterson M. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study Gut 2005 54 1693-1698 
Popescu I. Fleshner P.R. Pezzullo J.C. Charlton P.A. Kosutic G. Senagore A.J. The Ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial Dis Colon Rectum 2010 53 126-134 
Ejskjaer N. Vestergaard E.T. Hellstr&#246;m P.M. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis Aliment Pharmacol Ther. 2009 29 1179-1187 
Lasseter K.C. Shaughnessy L. Cummings D. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study J Clin Pharmacol. 2008 48 193-202 
Wang C.P. Kao C.H. Chen W.K. Lo W.Y. Hsieh C.L. A single-blinded, randomized pilot study evaluating effects of electroacupuncture in diabetic patients with symptoms suggestive of gastroparesis J Altern Complement Med. 2008 14 833-839 
Mearin F. Camilleri M. Malagelada J.R. Pyloric dysfunction in diabetics with recurrent nausea and vomiting Gastroenterology 1986 90 1919-1925 
Camilleri M. Brown M.L. Malagelada J.R. Relationship between impaired gastric emptying and abnormal gastrointestinal motility Gastroenterology 1986 91 94-99 
Jankovic J. Brin M.F. Therapeutic uses of botulinum toxin N Engl J Med. 1991 324 1186-1194 
Pehlivanov N. Pasricha P.J. Achalasia: botox, dilatation or laparoscopic surgery in 2006 Neurogastroenterol Motil. 2006 18 799-804 
Park M.I. Camilleri M. Gastroparesis: clinical update Am J Gastroenterol 2006 101 1129-1139 
Arts J. Holvoet L. Caenepeel P. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis Aliment Pharmacol Ther. 2007 26 1251-1258 
Friedenberg F.K. Palit A. Parkman H.P. Hanlon A. Nelson D.B. Botulinum toxin A for the treatment of delayed gastric emptying Am J Gastroenterol. 2008 103 416-423 
http://www.nice.org.uk/nicemedia/live/11130/31200/31200.pdf 
Anand C. Al-Juburi A. Familoni B. Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers Digestion 2007 75 83-89 
Abell T.L. Malinowski S. Minocha A. Nutrition aspects of gastroparesis and therapies for drug-refractory patients Nutr Clin Pract. 2006 21 23-33 
Cutts T.F. Luo J. Starkebaum W. Rashed H. Abell T.L. Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil. 2005 17 35-43 
Maranki J. Parkman H.P. Gastric electric stimulation for the treatment of gastroparesis Curr Gastroenterol Rep. 2007 9 286-294 
Maranki J.L. Lytes V. Meilahn J.E. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis Dig Dis Sci. 2008 53 2072-2078 
Jones M.P. Maganti K. A systematic review of surgical therapy for gastroparesis Am J Gastroenterol. 2003 98 2122-2129 
